Artemisia Annua (Sweet Wormwood) and osteoarthritis

What 2 graded rows on artemisia annua (sweet wormwood) agree on for osteoarthritis, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Artemisia Annua (Sweet Wormwood) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Artemisia Annua (Sweet Wormwood) page, with its PubMed record.

Supplement

Artemisia Annua (Sweet Wormwood) Choose another

2 rows · 70 people

Split. 1 row found an improvement and 1 had mixed results.

Mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

The best-graded row, grade D, is a pilot trial of 42 people (2016) and reported mixed results.

The rows run from 28 to 42 people, published in 2016: 2 single studies.

1 improved · 1 mixed

Grade DLonger-term tolerability and WOMAC scores · Improved
Open-label trial · n 28 · 2016 · Completers of the pilot trial (34 entered, 28 completed)
Not stated in the abstract · 6 months
The extract was well tolerated for up to 9 months in total, and WOMAC improvements seen in the double-blind phase were maintained.
Row on the Artemisia Annua (Sweet Wormwood) page · PubMed 27806033 (opens PubMed)
Grade DPain, stiffness and function (WOMAC) in hip or knee osteoarthritis · Mixed
Pilot RCT · n 42 · 2016 · Adults with hip or knee osteoarthritis (14 per group)
150 mg or 300 mg twice daily · 12 weeks
Low dose: WOMAC total improved from baseline (−12.2, p = 0.0159) and VAS pain fell by 21.4 mm (p = 0.0082). Placebo (−7.8, p = 0.10) and the high dose showed no significant change from baseline. The low dose was well tolerated.
Row on the Artemisia Annua (Sweet Wormwood) page · PubMed 26631103 (opens PubMed)